Asset Details
Do you wish to reserve the book?
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
Do you wish to request the book?
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
2013
Overview
A pooled post-hoc analysis of the phase 3, randomized, placebo-controlled BLISS trials (1684 patients with active systemic lupus erythematosus (SLE)) was performed to evaluate the effect of belimumab on renal parameters in patients with renal involvement at baseline, and to explore whether belimumab offered additional renal benefit to patients receiving mycophenolate mofetil at baseline. In addition to belimumab or placebo, all patients received standard SLE therapy. Patients with severe active lupus nephritis were excluded from the trials. Over 52 weeks, rates of renal flare, renal remission, renal organ disease improvement (assessed by Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index and British Isles Lupus Assessment Group), proteinuria reduction, grade 3/4 proteinuria, and serologic activity favored belimumab, although the between-group differences in most renal outcomes were not significant. Among the 267 patients with renal involvement at baseline, those receiving mycophenolate mofetil or with serologic activity at baseline had greater renal organ disease improvement with belimumab than with placebo. Limitations of this analysis included the small patient numbers and the post-hoc nature of this pooled analysis. The results suggest that belimumab may offer renal benefit in patients with SLE. Further study is warranted in patients with severe active lupus nephritis.
Publisher
SAGE Publications,Sage Publications Ltd
Subject
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Asia
/ Europe
/ Humans
/ Immunosuppressive Agents - therapeutic use
/ Kidney
/ Lupus
/ Lupus Erythematosus, Systemic - blood
/ Lupus Erythematosus, Systemic - complications
/ Lupus Erythematosus, Systemic - diagnosis
/ Lupus Erythematosus, Systemic - drug therapy
/ Lupus Nephritis - drug therapy
/ Mycophenolic Acid - analogs & derivatives
/ Mycophenolic Acid - therapeutic use
/ Patients
/ Proteins
